Derma Sciences Inc. (DSCI) Given Average Rating of “Hold” by Brokerages
Shares of Derma Sciences Inc. (NASDAQ:DSCI) have been given a consensus recommendation of “Hold” by the six brokerages that are covering the stock. Four analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $8.00.
A number of research firms have commented on DSCI. Zacks Investment Research downgraded Derma Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 11th. TheStreet raised Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th.
Several hedge funds and other institutional investors have recently made changes to their positions in DSCI. BlackRock Institutional Trust Company N.A. boosted its position in shares of Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock worth $603,000 after buying an additional 3,613 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock worth $3,163,000 after buying an additional 8,376 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock worth $207,000 after buying an additional 7,086 shares in the last quarter. Emerald Acquisition Ltd. purchased a new position in shares of Derma Sciences during the second quarter worth $202,000. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock worth $364,000 after buying an additional 73,911 shares in the last quarter. Institutional investors and hedge funds own 62.44% of the company’s stock.
Derma Sciences (NASDAQ:DSCI) traded up 0.543% during midday trading on Tuesday, hitting $4.625. 22,349 shares of the stock were exchanged. The stock’s market cap is $130.91 million. The firm has a 50-day moving average price of $4.68 and a 200-day moving average price of $4.24. Derma Sciences has a one year low of $2.85 and a one year high of $5.99.
Derma Sciences (NASDAQ:DSCI) last issued its quarterly earnings results on Tuesday, August 9th. The company reported $0.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.16. Derma Sciences had a negative return on equity of 11.74% and a negative net margin of 21.19%. The firm earned $22.20 million during the quarter, compared to the consensus estimate of $22.40 million. On average, equities research analysts anticipate that Derma Sciences will post ($0.04) EPS for the current fiscal year.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
Receive News & Stock Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related stocks with our FREE daily email newsletter.